Tempus
600 West Chicago Avenue
Suite 775
Chicago
Ilinois
60654-2526
United States
Website: https://www.tempus.com/
46 articles about Tempus
-
Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO
5/31/2020
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes.
-
Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology
5/30/2020
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic.
-
Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones
5/29/2020
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials.
-
BioSpace Movers & Shakers, Nov. 1
11/1/2019
Companies strengthen their leadership teams and boards of directors with this week's slate of Movers & Shakers. -
Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors
10/29/2019
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors.
-
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
-
Tempus Data Analytics Firm Hits $2 Billion Valuation, One of a Handful of Chicago “Unicorns”
9/5/2018
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion. -
Tempus to Participate in the NCI-MATCH Clinical Trial
8/2/2018
Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial
-
Tempus Announces Latest Immunotherapy Project
11/15/2017
The company announced a new research collaboration aimed at identifying which patients will respond positively to immunotherapy treatment, the next generation of cancer care.
-
Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care
10/19/2017
Tempus xT analyzes 595 genes relevant to the diagnosis, prognosis and therapeutic targeting of cancer.
-
Tempus And The Oregon Health & Science University (OHSU) Knight Cancer Institute Collaborating On Personalized Medicine Data Initiative
9/28/2017
-
Tempus Announces $130 Million Raised
9/25/2017
-
Tempus And Cleveland Clinic Collaborate On Personalized Medicine Initiative
9/15/2017
-
Tempus And UC Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership For Cancer Patients
8/31/2017
-
Tempus Selected As Sequencing And Analytics Provider By The Prostate Cancer Clinical Trials Consortium For Phase II Clinical Trial
8/17/2017
-
Tempus Selected By University of Virginia As Partner For Large Granular Lymphocyte Leukemia Research Project
8/3/2017
-
Tempus To Assist University of California, San Diego (UCSD) In Personalized Medicine Initiative
7/6/2017
-
Tempus And University of Michigan Collaborate On Breast Cancer Initiative
6/8/2017
-
Tempus And Northwestern Expand Partnership To Accelerate Personalized Medicine Efforts
5/12/2017
-
Erik Phelps Joins Tempus As Executive Vice President And General Counsel
4/5/2017